Doxofylline: A New Generation Xanthine Bronchodilator Devoid of Major Cardiovascular Adverse Effects
Summary Doxofylline (7-(1,3-dioxalan-2-ylmethyl) theophylline) is a novel xanthine bronchodilator which differs from theophylline in that it contains a dioxalane group in position 7. Similarly to theophylline, its mechanism of action is related to the inhibition of phosphodiesterase activities, but...
Saved in:
| Published in: | Current medical research and opinion Vol. 16; no. 4; pp. 258 - 268 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Informa UK Ltd
2000
Taylor & Francis |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Summary
Doxofylline (7-(1,3-dioxalan-2-ylmethyl) theophylline) is a novel xanthine bronchodilator which differs from theophylline in that it contains a dioxalane group in position 7. Similarly to theophylline, its mechanism of action is related to the inhibition of phosphodiesterase activities, but in contrast it appears to have decreased affinities towards adenosine A1 and A2 receptors, which may account for its better safety profile. The bronchodilating activities of doxofylline have been demonstrated in clinical trials involving patients with either bronchial asthma or chronic obstructive pulmonary disease. In contrast to other bronchodilators, experimental and clinical studies have shown that the drug is devoid of direct stimulatory effects. This may be of importance because the arrhythmogenic actions of bronchodilators may have a negative impact on the survival of patients with respiratory diseases. |
|---|---|
| AbstractList | Summary
Doxofylline (7-(1,3-dioxalan-2-ylmethyl) theophylline) is a novel xanthine bronchodilator which differs from theophylline in that it contains a dioxalane group in position 7. Similarly to theophylline, its mechanism of action is related to the inhibition of phosphodiesterase activities, but in contrast it appears to have decreased affinities towards adenosine A1 and A2 receptors, which may account for its better safety profile. The bronchodilating activities of doxofylline have been demonstrated in clinical trials involving patients with either bronchial asthma or chronic obstructive pulmonary disease. In contrast to other bronchodilators, experimental and clinical studies have shown that the drug is devoid of direct stimulatory effects. This may be of importance because the arrhythmogenic actions of bronchodilators may have a negative impact on the survival of patients with respiratory diseases. Doxofylline (7-(1,3-dioxalan-2-ylmethyl) theophylline) is a novel xanthine bronchodilator which differs from theophylline in that it contains a dioxalane group in position 7. Similarly to theophylline, its mechanism of action is related to the inhibition of phosphodiesterase activities, but in contrast it appears to have decreased affinities towards adenosine A1 and A2 receptors, which may account for its better safety profile. The bronchodilating activities of doxofylline have been demonstrated in clinical trials involving patients with either bronchial asthma or chronic obstructive pulmonary disease. In contrast to other bronchodilators, experimental and clinical studies have shown that the drug is devoid of direct stimulatory effects. This may be of importance because the arrhythmogenic actions of bronchodilators may have a negative impact on the survival of patients with respiratory diseases. |
| Author | Dini, Frank Lloyd Cogo, Roberto |
| Author_xml | – sequence: 1 givenname: Frank Lloyd surname: Dini fullname: Dini, Frank Lloyd email: frankld@tin.it organization: 1Unità Operativa di Cardiologia, Ospedale Villamarina, Piombino, Italy – sequence: 2 givenname: Roberto surname: Cogo fullname: Cogo, Roberto email: frankld@tin.it organization: 1Unità Operativa di Cardiologia, Ospedale Villamarina, Piombino, Italy |
| BookMark | eNp9kMlOwzAQhi0EEmW5c_QLBOzaaWw4lZZNYrmAxC2a2GPFVbCRnbb07UkFF5DgNBp9-mb5D8huiAEJOeHslHNVnjHBWKU145rzirFyh4y4rEQhVVXtktEWFwMv98lBzgvG-FhpPSJ2Hj-i23SdD3hOp_QR1_QGAybofQz0FULfDohephhMG63voI-JznEVvaXR0QdYDP0MkvVxBdksO0h0aleYMtIr59D0-YjsOegyHn_XQ_JyffU8uy3un27uZtP7wgxXl4XTAJpLKZEp4BPFZKNh3IiykWUzFlIKC1wiKq0a4cagbNkIrLQwlWUTZcQhYV9zTYo5J3T1e_JvkDY1Z_U2pfp3SoNy8aX44GJ6g3VMna172HQxuQTB-FyLf-zzH3aL0PWtgYT1Ii5TGJ79e_UnMSuBLw |
| CitedBy_id | crossref_primary_10_1016_j_heliyon_2018_e00829 crossref_primary_10_5155_eurjchem_2_3_372_377_396 crossref_primary_10_1016_j_pupt_2018_09_007 crossref_primary_10_1016_j_jct_2020_106126 |
| Cites_doi | 10.1378/chest.99.6.1415 10.1016/0002-9149(83)90578-7 10.1001/archinte.159.6.585 10.1016/S0033-0620(05)80018-0 10.1111/j.1540-8159.1993.tb00987.x 10.1378/chest.101.6.1703 10.1164/ajrccm.154.6.8970341 10.1016/0002-8703(85)90653-2 10.1007/BF00561059 10.1161/01.CIR.96.6.1914 10.1136/bmj.306.6884.1034 10.1159/000196177 10.1056/NEJM199605233342101 10.1038/clpt.1984.111 10.1093/eurheartj/14.6.744 10.1378/chest.88.6.931 10.1093/oxfordjournals.eurheartj.a060878 10.1159/000196340 10.1016/0306-9877(82)90013-5 10.1097/00063198-200003000-00003 10.1016/0002-8703(87)90666-1 10.1159/000175944 10.1378/chest.114.2.411 10.1016/S0140-6736(87)91057-9 10.1183/09031936.94.07030579 10.1016/S0002-9149(84)80133-2 10.1016/S0033-0620(85)80003-7 10.1056/NEJM199202203260801 10.1093/eurheartj/6.suppl_A.29 10.1136/hrt.50.2.135 10.1056/NEJM198207223070401 10.1378/chest.101.6.1699 10.1093/eurheartj/17.suppl_B.17 |
| ContentType | Journal Article |
| Copyright | 2000 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2000 |
| Copyright_xml | – notice: 2000 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2000 |
| DBID | AAYXX CITATION |
| DOI | 10.1185/0300799019117005 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1473-4877 |
| EndPage | 268 |
| ExternalDocumentID | 10_1185_0300799019117005 11171439 |
| Genre | Research Article |
| GroupedDBID | --- .55 .GJ 00X 03L 08R 0BK 0R~ 29F 34G 39C 3V. 4.4 53G 5GY 5RE 6J9 6PF 7X7 88E 88I 8AF 8AO 8FI 8FJ 8R4 8R5 AAJNR AALIY AALUX AAMIU AAPUL AAPXX AAQRR AAUGY AAWTL ABBAB ABBKH ABEIZ ABIVO ABLJU ABLKL ABOCM ABPTK ABUPF ABUWG ABWCV ABZEW ACENM ACFUF ACGFO ACGFS ACGOD ACKZS ACLSK ADBBV ADCVX ADFCX ADFOM ADFZZ ADRBQ AECIN AEIIZ AENEX AEOZL AEYQI AFKRA AFLEI AFWLO AGDLA AGFJD AGRBW AGYJP AHMBA AIJEM AIRBT AJVHN AKBVH ALIIL ALMA_UNASSIGNED_HOLDINGS ALQZU AMDAE AZQEC BABNJ BENPR BLEHA BOHLJ BPHCQ BRMBE BVXVI CAG CCCUG COF CS3 CYYVM CZDIS DKSSO DRXRE DU5 DWQXO DWTOO EBS EJD F5P FYUFA GNUQQ H13 HCIFZ HZ~ IPNFZ J5H JENTW KRBQP KSSTO KWAYT KYCEM L7B LJTGL M1P M2P M2Q M44 M4Z O9- P2P PQEST PQQKQ PQUKI PROAC PSQYO Q2X QQXMO RIG RNANH RVRKI RWL S0X SJN TAE TFDNU TFL TFW UEQFS UKHRP V1S X7M ZGI ~1N AAORF AAYXX ABJNI ABLIJ ABXYU ACIEZ ALIPV ALYBC CCPQU CITATION EMOBN HMCUK NUSFT TBQAZ TDBHL TERGH TUROJ |
| ID | FETCH-LOGICAL-c1915-f9aa91444e08a16804b9a2b35b45b23443da14ee898b3f2a8d5b3e793c7d068c3 |
| ISSN | 0300-7995 |
| IngestDate | Thu Nov 21 21:56:42 EST 2024 Tue Jun 13 19:22:28 EDT 2023 Wed Jun 21 08:14:59 EDT 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c1915-f9aa91444e08a16804b9a2b35b45b23443da14ee898b3f2a8d5b3e793c7d068c3 |
| PageCount | 11 |
| ParticipantIDs | informaworld_taylorfrancis_310_1185_0300799019117005 crossref_primary_10_1185_0300799019117005 informahealthcare_journals_10_1185_0300799019117005 |
| PublicationCentury | 2000 |
| PublicationDate | 20000000 1/1/2000 2000-01-00 |
| PublicationDateYYYYMMDD | 2000-01-01 |
| PublicationDate_xml | – year: 2000 text: 20000000 |
| PublicationDecade | 2000 |
| PublicationTitle | Current medical research and opinion |
| PublicationYear | 2000 |
| Publisher | Informa UK Ltd Taylor & Francis |
| Publisher_xml | – name: Informa UK Ltd – name: Taylor & Francis |
| References | CIT0032 Checchini M. (CIT0048) 1997; 45 CIT0031 A randomized trial of propanolol in patients with acute myocardial infarction (CIT0025) 1714; 247 Cirillo R. (CIT0041) 1988; 295 Dini F. L (CIT0045) 1991; 49 Dini F. L. (CIT0058) 1993; 13 CIT0035 CIT0037 Chazan R. (CIT0033) 1995; 33 CIT0039 CIT0001 Villani F. (CIT0051) 1997; 35 CIT0002 Bagnato G. F. (CIT0044) 1989; 11 CIT0004 CIT0007 CIT0006 CIT0009 CIT0052 Cirillo R. (CIT0042) 1989; 65 CIT0010 Hendeles L. (CIT0034) 1977; 1 Giorgi M. (CIT0047) 1993; 6 CIT0054 CIT0053 CIT0012 Cipri A. (CIT0046) 1992; 40 CIT0011 CIT0055 Franzone J. S. (CIT0040) 1988; 14 Shizukuda Y. (CIT0020) 1998; 275 Mirabelli S. (CIT0056) 2000; 12 CIT0014 St John Sutton M. (CIT0019) 1997; 96 CIT0013 Evoniuk G. (CIT0043) 1987; 242 CIT0016 CIT0015 CIT0018 CIT0017 Biaggioni I. (CIT0036) 1991; 258 McFadden E. R. (CIT0003) 1992 Kurachi Y (CIT0030) 1995 CIT0021 CIT0023 CIT0022 Holford F. D. (CIT0005) 1973; 108 Dini F. L (CIT0057) 1995; 16 Melillo G. (CIT0049) 1989; 9 CIT0024 CIT0027 CIT0026 CIT0029 CIT0028 Dini F. L (CIT0050) 2000; 40 Peerson C. G. A (CIT0038) 1985 |
| References_xml | – volume: 108 start-page: 879 year: 1973 ident: CIT0005 publication-title: Am. Rev. Resp. Dis contributor: fullname: Holford F. D. – ident: CIT0004 doi: 10.1378/chest.99.6.1415 – volume: 9 start-page: 397 year: 1989 ident: CIT0049 publication-title: Int. J. Clin. Pharm. Res contributor: fullname: Melillo G. – ident: CIT0039 doi: 10.1016/0002-9149(83)90578-7 – ident: CIT0018 doi: 10.1001/archinte.159.6.585 – volume: 11 start-page: 29 year: 1989 ident: CIT0044 publication-title: Eur. Rev. Pharmacol. Sci contributor: fullname: Bagnato G. F. – ident: CIT0053 doi: 10.1016/S0033-0620(05)80018-0 – ident: CIT0032 doi: 10.1111/j.1540-8159.1993.tb00987.x – ident: CIT0010 doi: 10.1378/chest.101.6.1703 – volume: 13 start-page: 305 year: 1993 ident: CIT0058 publication-title: Int. J. Clin. Pharm. Res contributor: fullname: Dini F. L. – volume: 295 start-page: 221 year: 1988 ident: CIT0041 publication-title: Arch. Int. Pharmacodyn contributor: fullname: Cirillo R. – ident: CIT0015 doi: 10.1164/ajrccm.154.6.8970341 – volume: 258 start-page: 89 year: 1991 ident: CIT0036 publication-title: J. Pharmacol. Expl. Ther contributor: fullname: Biaggioni I. – volume: 49 start-page: 978 year: 1991 ident: CIT0045 publication-title: Cum Ther. Res contributor: fullname: Dini F. L – volume: 45 start-page: 185 year: 1997 ident: CIT0048 publication-title: Minerva Cardioangiol contributor: fullname: Checchini M. – ident: CIT0016 doi: 10.1016/0002-8703(85)90653-2 – ident: CIT0031 doi: 10.1007/BF00561059 – volume: 40 start-page: 31 year: 1992 ident: CIT0046 publication-title: Minerva Cardioangiol contributor: fullname: Cipri A. – ident: CIT0023 doi: 10.1161/01.CIR.96.6.1914 – ident: CIT0012 doi: 10.1136/bmj.306.6884.1034 – volume: 12 start-page: S22 year: 2000 ident: CIT0056 publication-title: Rev. Colomb. Neumolog contributor: fullname: Mirabelli S. – ident: CIT0054 doi: 10.1159/000196177 – volume: 40 start-page: 1051 year: 2000 ident: CIT0050 publication-title: J. Cl. Pharmacol contributor: fullname: Dini F. L – start-page: pp. 789 volume-title: Physiology and Pathophysiology of the Heart year: 1995 ident: CIT0030 contributor: fullname: Kurachi Y – ident: CIT0027 doi: 10.1056/NEJM199605233342101 – volume: 33 start-page: 170 year: 1995 ident: CIT0033 publication-title: Int. J. Clin. Pharmacol. Ther contributor: fullname: Chazan R. – ident: CIT0022 doi: 10.1038/clpt.1984.111 – ident: CIT0055 doi: 10.1093/eurheartj/14.6.744 – ident: CIT0035 doi: 10.1378/chest.88.6.931 – volume: 35 start-page: 107 year: 1997 ident: CIT0051 publication-title: Int. J. Cl. Pharm. Ther contributor: fullname: Villani F. – volume: 1 start-page: 13 year: 1977 ident: CIT0034 publication-title: Drug Intell. Clin. Pharmacol contributor: fullname: Hendeles L. – volume: 16 start-page: 151 year: 1995 ident: CIT0057 publication-title: Eur. Heart J doi: 10.1093/oxfordjournals.eurheartj.a060878 contributor: fullname: Dini F. L – volume: 275 start-page: H961–H968 year: 1998 ident: CIT0020 publication-title: Am. J. Physiol contributor: fullname: Shizukuda Y. – volume: 6 start-page: 417 issue: 17 year: 1993 ident: CIT0047 publication-title: Eur. Respir. J contributor: fullname: Giorgi M. – ident: CIT0011 doi: 10.1159/000196340 – ident: CIT0037 doi: 10.1016/0306-9877(82)90013-5 – ident: CIT0001 doi: 10.1097/00063198-200003000-00003 – ident: CIT0017 doi: 10.1016/0002-8703(87)90666-1 – volume: 14 start-page: 479 year: 1988 ident: CIT0040 publication-title: Drug Explt. Clin. Res contributor: fullname: Franzone J. S. – ident: CIT0052 doi: 10.1159/000175944 – ident: CIT0009 doi: 10.1378/chest.114.2.411 – ident: CIT0007 doi: 10.1016/S0140-6736(87)91057-9 – volume: 247 start-page: 1707– year: 1714 ident: CIT0025 publication-title: JAMA contributor: fullname: A randomized trial of propanolol in patients with acute myocardial infarction – volume: 96 start-page: 324 year: 1997 ident: CIT0019 publication-title: Circulation contributor: fullname: St John Sutton M. – volume: 65 start-page: 21 year: 1989 ident: CIT0042 publication-title: Res. Com. Chem. Path. Pharmacol contributor: fullname: Cirillo R. – ident: CIT0002 doi: 10.1183/09031936.94.07030579 – start-page: pp. 115 volume-title: Pharmacology of Asthma year: 1985 ident: CIT0038 contributor: fullname: Peerson C. G. A – ident: CIT0006 doi: 10.1016/S0002-9149(84)80133-2 – ident: CIT0028 doi: 10.1016/S0033-0620(85)80003-7 – start-page: pp. 1581 volume-title: Heart Disease year: 1992 ident: CIT0003 contributor: fullname: McFadden E. R. – ident: CIT0013 doi: 10.1056/NEJM199202203260801 – ident: CIT0021 doi: 10.1093/eurheartj/6.suppl_A.29 – ident: CIT0026 doi: 10.1136/hrt.50.2.135 – volume: 242 start-page: 882 year: 1987 ident: CIT0043 publication-title: J. Pharmacol. Exp. Ther contributor: fullname: Evoniuk G. – ident: CIT0024 doi: 10.1056/NEJM198207223070401 – ident: CIT0014 doi: 10.1378/chest.101.6.1699 – ident: CIT0029 doi: 10.1093/eurheartj/17.suppl_B.17 |
| SSID | ssj0012899 |
| Score | 1.5946507 |
| Snippet | Summary
Doxofylline (7-(1,3-dioxalan-2-ylmethyl) theophylline) is a novel xanthine bronchodilator which differs from theophylline in that it contains a... Doxofylline (7-(1,3-dioxalan-2-ylmethyl) theophylline) is a novel xanthine bronchodilator which differs from theophylline in that it contains a dioxalane group... |
| SourceID | crossref informaworld informahealthcare |
| SourceType | Aggregation Database Publisher |
| StartPage | 258 |
| SubjectTerms | Arrhythmogenic Asthma Bronchodilators Chronic obstructive pulmonary disease Doxofylline Theophylline |
| Title | Doxofylline: A New Generation Xanthine Bronchodilator Devoid of Major Cardiovascular Adverse Effects |
| URI | https://www.tandfonline.com/doi/abs/10.1185/0300799019117005 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9wwEBabBEovIX3RpA906KUEU9uSVnJvy-6WQppcmkBuRi83227XIZtA8-87evi1ISUt9GLWYm1jzefRjGbmG4TecS61zDObEFhdEiqsThQ3PAHb1LjAWEasb2L7lZ-ci9mczkejZo-sG_uvkoYxkLWrnP0Labc3hQH4DTKHI0gdjg-S-6z-VVe3S08g6qvOXQZjIJf2oj6HqbxwpiU44CvQfWaxdH63yx6qFyZkxHyH8-kwUdU3bl7bw8B2vO7btA3F088Y84n8QaFkztVj9UL9s4VvIeXt5R-HX5b1rWmjIPW3usv1rgfbEWnnnMbyqbOjXkKSr8tK08TRzoUVJ6hZygkAIzZwafTwuIc32leqgdw9rs95aMNzV_ULz5IBT-Mu1le4ljop65a5NvnQuz2ClZt_3UI7OWgrUJY7k-n85LgNRjmfNASjwos00W7BPmzeY2Dd7EXu24s2k2-DD7dnyZzuod3oguBJwM4TNLKrp-jRcUyyeIZMD0If8QQDgHAHINwACA8BhAOAcF1hDyA8BBCOAMIRQM_R2af56fRzEptxJBpejiVVIWUB3je1qZDZWKRUFTJXhCnKVE4oJUZm1FpRCEWqXArDFLEwn5qbdCw0eYG2V_XKvkSYaJrZlMtKZxVVuipyYzUzRBhKVEXZPnrfTGJ5GThXyvuEto_InVku4-e4_sNVtC-H8trvjlWhlU1J7rvs4J8e9go9DvwNbt_uNdq-vrqxb9DW2ty8jUj7DTMampA |
| link.rule.ids | 315,782,786,4029,27933,27934,27935,59870,60659,61277,61458 |
| linkProvider | Taylor & Francis |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JTwIxFG4UEvWiuEVce_DiYeLMtGU6Jh4ISzACFzHhNukaMIYxAkb_ve10IIDLQY-TyZs087Z-fa_fA-AyiphgYaA8ZLKLh6kSHo9k5Jm9qbSFsQCpbIjtQ9Tt03rD0uTczu7C2LZKi6G1I4rIYrV1bnsY7TyckmtjmH5kCzqxnZtiGUyLxGBnvwCK1Vqj25mXESyacGUE37PMZ7M65TffWMpLpZy1dDDvwVphMl3IQc2df66-BLbzzSesOmvZBWtqtAc2Onl5fR_Ievqe6g9L061uYBWaCAgdL7VVH-wbLQzMK2iw-8iETTl8tpAd1tVbOpQw1bDDnsxzbanHFWYzn8cKOqLk8QF4bDZ6tZaXj2HwhFki8XTMWGxwF1Y-ZUGF-pjHLOSIcEx4iDBGkgVYKRpTjnTIqCQcKeP3IpJ-hQp0CAqjdKSOAEQCB8qPmBaBxlzoOJRKEImoxIhrTMrgaqaE5MWxbSQZSqEkWf1tZYC-aCnJHXD8ixRe1GMyyc5FtBtikqCfxI7_JnYBNlu9Tjtp33XvT8CWu8Zvj29OQWHyOlVnYH0sp-e52X4CZcLpUQ |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB60heJF64Z1nYMXD8EkM2km4qU0LYq2CCr0FmalFUmKaUX_vTOZtNi6HPQYwgtD3jZvvjffA-A0DCmnvicdpLOLg4nkDgtF6Oi9qTDAmIdkMcT2PuwPSNwxNDmXs7swpq3S1NDKEkUUsdo491go6-AkONd26YYGz4nM2BRDYFptGniwAqqtdqffm6MIppiwKILrGOKzGUz5zTcW0lK9JC0dzluwlohMP6Wg7sb_Fl8H6-XWE7asrWyCFZlugVqvBNe3gYizt0y9G5JueQFbUMc_aFmpjfLgQOtgqF9BXbmnOmiK0bMp2GEsX7ORgJmCPfqkn9sLHa6wmPicS2hpkvMd8NjtPLSvnHIIg8P1EgNHRZRGuurC0iXUaxIXs4j6DAUMB8xHGCNBPSwliQhDyqdEBAxJ7fU8FG6TcLQLKmmWyj0AEceedEOquKcw4yryheSBQERgxBQOGuBspoNkbLk2kqJGIUGy_NsaAH1RUlK6X_6LFP6sxmRSnIooO8IkQT-J7f9N7ATU7uJucnvdvzkAa_YOvzm7OQSVyctUHoHVXEyPS6P9AKiy5_4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Doxofylline%3A+A+New+Generation+Xanthine+Bronchodilator+Devoid+of+Major+Cardiovascular+Adverse+Effects&rft.jtitle=Current+medical+research+and+opinion&rft.au=Dini%2C+Frank+Lloyd&rft.au=Cogo%2C+Roberto&rft.date=2000&rft.pub=Informa+UK+Ltd&rft.issn=0300-7995&rft.eissn=1473-4877&rft.volume=16&rft.issue=4&rft.spage=258&rft.epage=268&rft_id=info:doi/10.1185%2F0300799019117005&rft.externalDocID=10_1185_0300799019117005 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-7995&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-7995&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-7995&client=summon |